Last Updated: 7 January 2025
Deciphex, a leader in AI-powered digital pathology, has successfully closed a $32.3 million Series C funding round. This marks a major step in their mission to tackle diagnostic delays and expand access to quality pathology services.
The round was led by Molten Ventures, with notable participation from ACT Venture Capital, Seroba, Charles River Laboratories (NYSE: CRL), IRRUS Investments, HBAN Medtech Syndicate, and Nextsteps Capital. These investors bring deep industry expertise to support Deciphex's ambitious goals.
Pathology is critical to healthcare, influencing over 70% of medical diagnoses. Yet, healthcare systems globally are struggling to keep up with the demand for pathology services due to a shortage of specialists. This gap results in backlogs, delayed diagnoses, and increased strain on healthcare providers.
"This investment accelerates our mission to transform global pathology access. Our ergonomic, AI-enabled platform enhances diagnostic workflow and accuracy - allowing experts to clear backlogs faster without compromising quality."
Donal O'Shea, Founder and CEO of Deciphex
Deciphex’s platforms, Diagnexia and Patholytix, address these challenges by enabling pathologists to work up to 40% faster while maintaining precision. By improving efficiency, Deciphex is helping healthcare systems worldwide deliver better, faster care to patients.
The new funding will enable Deciphex to expand its operations globally, focusing on key markets such as the US, UK, EU, Canada, and Japan. The company aims to enhance its core platforms to meet the growing demand for digital pathology solutions and research services in healthcare and pharmaceuticals.
Deciphex plans to invest heavily in developing its AI models, leveraging its extensive pathology image repository to improve diagnostic speed and accuracy.
Additionally, the company is deepening partnerships with leaders like Novartis and Charles River Laboratories to advance preclinical safety evaluation and toxicology research. Expanding these collaborations will help Deciphex continue driving innovation in pathology.
Founded in 2017 by Donal O'Shea, Deciphex specializes in using AI to revolutionize pathology workflows. The company offers two flagship platforms:
Deciphex's commitment to improving diagnostic workflows has positioned it as a trailblazer in the field.
By automating routine tasks, its tools allow pathologists to focus on complex cases, leading to better outcomes for patients and faster drug development timelines.
Deciphex has garnered support from a mix of institutional and strategic investors:
This latest round builds on previous investments, reflecting sustained confidence in Deciphex’s vision and execution. The expertise of these investors ensures the company is well-positioned to scale its operations and make a lasting impact on the global pathology landscape.
